BACKGROUND/AIMS: The value of the Framingham equation in predicting cardiovascular risk in African Americans and patients with chronic kidney disease (CKD) is unclear. The purpose of the study was to evaluate whether the addition of CKD and race to the Framingham equation improves risk stratification in hypertensive patients. METHODS: Participants in the ALLHAT were studied. Those randomized to doxazosin, older than 74 years, and those with a history of coronary heart disease were excluded. Two risk stratification models were developed using Cox proportional hazards models in a two-thirds developmental sample. The first model included the traditional Framingham risk factors. The second model included the traditional risk factors plus CKD, defined by estimated glomerular filtration rate categories, and stratification by race (black vs non-black). The primary outcome was a composite of fatal coronary heart disease, nonfatal myocardial infarction, coronary revascularization, and hospitalized angina. RESULTS: There were a total of 19,811 eligible subjects. In the validation cohort, there was no difference in C-statistics between the Framingham equation and the ALLHAT model including CKD and race. This was consistent across subgroups by race and sex and among those with CKD. One exception was among Non-Black women where the C-statistic was higher for the Framingham equation (0.68 vs 0.65, P = .02). In addition, net reclassification improvement was not significant for any subgroup based on race and sex, ranging from -5.5% to 4.4%. CONCLUSION: The addition of CKD status and stratification by race does not improve risk prediction in high-risk hypertensive patients.
BACKGROUND/AIMS: The value of the Framingham equation in predicting cardiovascular risk in African Americans and patients with chronic kidney disease (CKD) is unclear. The purpose of the study was to evaluate whether the addition of CKD and race to the Framingham equation improves risk stratification in hypertensivepatients. METHODS:Participants in the ALLHAT were studied. Those randomized to doxazosin, older than 74 years, and those with a history of coronary heart disease were excluded. Two risk stratification models were developed using Cox proportional hazards models in a two-thirds developmental sample. The first model included the traditional Framingham risk factors. The second model included the traditional risk factors plus CKD, defined by estimated glomerular filtration rate categories, and stratification by race (black vs non-black). The primary outcome was a composite of fatal coronary heart disease, nonfatal myocardial infarction, coronary revascularization, and hospitalized angina. RESULTS: There were a total of 19,811 eligible subjects. In the validation cohort, there was no difference in C-statistics between the Framingham equation and the ALLHAT model including CKD and race. This was consistent across subgroups by race and sex and among those with CKD. One exception was among Non-Black women where the C-statistic was higher for the Framingham equation (0.68 vs 0.65, P = .02). In addition, net reclassification improvement was not significant for any subgroup based on race and sex, ranging from -5.5% to 4.4%. CONCLUSION: The addition of CKD status and stratification by race does not improve risk prediction in high-risk hypertensivepatients.
Authors: Mark R Nelson; Philip Ryan; Andrew M Tonkin; Emmae Ramsay; Kristyn Willson; Lindon W H Wing; Christopher M Reid Journal: Hypertension Date: 2010-05-24 Impact factor: 10.190
Authors: Josef Coresh; Brad C Astor; Geraldine McQuillan; John Kusek; Tom Greene; Frederick Van Lente; Andrew S Levey Journal: Am J Kidney Dis Date: 2002-05 Impact factor: 8.860
Authors: Brenda R Hemmelgarn; Braden J Manns; Anita Lloyd; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Marcello Tonelli Journal: JAMA Date: 2010-02-03 Impact factor: 56.272
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Sylvie Bastuji-Garin; Anne Deverly; Dominique Moyse; Alain Castaigne; Giuseppe Mancia; Peter W de Leeuw; Luis M Ruilope; Talma Rosenthal; Gilles Chatellier Journal: J Hypertens Date: 2002-10 Impact factor: 4.844
Authors: Mahboob Rahman; Sara Pressel; Barry R Davis; Chuke Nwachuku; Jackson T Wright; Paul K Whelton; Joshua Barzilay; Vecihi Batuman; John H Eckfeldt; Michael A Farber; Stanley Franklin; Mario Henriquez; Nelson Kopyt; Gail T Louis; Mohammad Saklayen; Carole Stanford; Candace Walworth; Harry Ward; Thomas Wiegmann Journal: Ann Intern Med Date: 2006-02-07 Impact factor: 25.391
Authors: Daniel E Weiner; Hocine Tighiouart; Essam F Elsayed; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak Journal: J Am Coll Cardiol Date: 2007-07-02 Impact factor: 24.094
Authors: Meredith C Foster; Andreea M Rawlings; Elizabeth Marrett; David Neff; Morgan E Grams; Bertram L Kasiske; Kerry Willis; Lesley A Inker; Josef Coresh; Elizabeth Selvin Journal: Am J Kidney Dis Date: 2013-12-25 Impact factor: 8.860
Authors: Lakhvir K Assi; Natasha McIntyre; Simon Fraser; Scott Harris; Colin A Hutchison; Chris W McIntyre; Paul Cockwell; Maarten W Taal Journal: PLoS One Date: 2015-07-01 Impact factor: 3.240
Authors: Sandro Marini; Umme K Lena; Katherine M Crawford; Charles J Moomaw; Fernando D Testai; Steven J Kittner; Michael L James; Daniel Woo; Carl D Langefeld; Jonathan Rosand; Christopher D Anderson Journal: Front Neurol Date: 2018-07-06 Impact factor: 4.003